SNS01-T Modulation of eIF5A Inhibits B-cell Cancer Progression and Synergizes With Bortezomib and Lenalidomide

The high rates of recurrence and low median survival in many B-cell cancers highlight a need for new targeted therapeutic modalities. In dividing cells, eukaryotic translation initiation factor 5A (eIF5A) is hypusinated and involved in regulation of protein synthesis and proliferation, whereas the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Francis, Sarah M, Taylor, Catherine A, Tang, Terence, Liu, Zhongda, Zheng, Qifa, Dondero, Richard, Thompson, John E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435495/
https://www.ncbi.nlm.nih.gov/pubmed/24569836
http://dx.doi.org/10.1038/mt.2014.24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435495/
https://www.ncbi.nlm.nih.gov/pubmed/24569836
http://dx.doi.org/10.1038/mt.2014.24

Ejemplares similares